Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech plans to start a Phase 3 trial.

The post Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3 appeared first on MedCity News.